NEO Stock Analysis: NeoGenomics | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 2.149m USD | 12M Return: 76.9% | US64049M2098 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 40.2M
Qual. Beats: 0
Rev. Trend: 99.9%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
NeoGenomics, Inc. (NASDAQ: NEO) is a mid-cap healthcare services company that operates a network of cancer-focused clinical laboratories across the United States and the United Kingdom. Founded in 2001 and headquartered in Fort Myers, Florida, the company provides a broad menu of oncology testing services to hospitals, academic centers, pathologists, oncologists, clinicians, clinical laboratories, and pharmaceutical companies. Its capabilities span cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry with digital imaging, molecular testing, and morphologic analysis. The company also supports pharmaceutical clients oncology drug development programs from discovery through commercialization, making it both a clinical diagnostic provider and a partner in the precision oncology and companion diagnostics space, an area that has grown in importance as targeted cancer therapies become more prevalent.
- Clinical Services volume growth accelerates test revenue
- Pharma Services backlog expands amid oncology trial demand
- Medicare reimbursement cuts pressure oncology test margins
| Net Income: -51.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA 0.83 > 1.0 |
| NWC/Revenue: 35.96% < 20% (prev 42.40%; Δ -6.44% < -1%) |
| CFO/TA 0.02 > 3% & CFO 22.0m > Net Income -51.9m |
| Net Debt (377.0m) to EBITDA (12.9m): 29.25 < 3 |
| Current Ratio: 3.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (26.2m) vs 12m ago 2.25% < -2% |
| Gross Margin: 42.92% > 18% (prev 43.91%; Δ -0.99% > 0.5%) |
| Asset Turnover: 55.81% > 50% (prev 49.44%; Δ 6.37% > 0%) |
| Interest Coverage Ratio: -20.37 > 6 (EBIT TTM -52.6m / Interest Expense TTM 2.58m) |
| A: 0.20 (Total Current Assets 381.5m - Total Current Liabilities 105.9m) / Total Assets 1.35b |
| B: -0.33 (Retained Earnings -448.7m / Total Assets 1.35b) |
| C: -0.04 (EBIT TTM -52.6m / Avg Total Assets 1.37b) |
| D: 1.39 (Book Value of Equity 785.7m / Total Liabilities 565.6m) |
| Altman-Z'' = 1.46 = BB |
| DSRI: 1.03 (Receivables 175.4m/153.6m, Revenue 766.3m/689.2m) |
| GMI: 1.02 (GM 43.91% / 42.92%) |
| AQI: 1.00 (AQ_t 0.59 / AQ_t-1 0.60) |
| SGI: 1.11 (Revenue 766.3m / 689.2m) |
| TATA: -0.05 (NI -51.9m - CFO 22.0m) / TA 1.35b) |
| Beneish M = -2.91 (Cap -4..+1) = A |
As of October 08, 2026, the stock is trading at USD 15.97 with a total of 3,191,762 shares traded. Over the past week, the price has changed by -13.02%, over one month by -9.05%, over three months by +10.14% and over the past year by +76.85%.
Current recommended Stop Loss: 14.40 (which is 9.8% or 1.5 ATR below the current price).
NeoGenomics has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy NEO.
- StrongBuy: 6
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 21.2 | 32.4% |
P/E Forward = 222.2222
P/S = 2.8046
P/B = 3.0021
P/EG = 2.0871
Revenue TTM = 766.3m USD
EBIT TTM = -52.6m USD
EBITDA TTM = 12.9m USD
Long Term Debt = 374.2m USD (from longTermDebt, last quarter)
Short Term Debt = 5.43m USD (from shortTermDebt, last quarter)
Debt = 522.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 74.1m
Net Debt = 377.0m USD (calculated: Debt 522.5m - CCE 145.5m)
Enterprise Value = 2.53b USD (2.15b + Debt 522.5m - CCE 145.5m)
Interest Coverage Ratio = -20.37 (Ebit TTM -52.6m / Interest Expense TTM 2.58m)
EV/FCF = -343.5x (Enterprise Value 2.53b / FCF TTM -7.36m)
FCF Yield = -0.29% (FCF TTM -7.36m / Enterprise Value 2.53b)
FCF Margin = -0.96% (FCF TTM -7.36m / Revenue TTM 766.3m)
Net Margin = -6.77% (Net Income TTM -51.9m / Revenue TTM 766.3m)
Gross Margin = 42.92% ((Revenue TTM 766.3m - Cost of Revenue TTM 437.4m) / Revenue TTM)
Gross Margin QoQ = 45.56% (prev 43.32%)
Tobins Q-Ratio = 1.87 (Enterprise Value 2.53b / Total Assets 1.35b)
Interest Expense / Debt = 0.49% (Interest Expense 2.58m / Debt 522.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -41.5m (EBIT -52.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.60 (Total Current Assets 381.5m / Total Current Liabilities 105.9m)
Debt / Equity = 0.66 (Debt 522.5m / totalStockholderEquity, last quarter 785.7m)
Debt / EBITDA = 29.25 (Net Debt 377.0m / EBITDA 12.9m)
Debt / FCF = -51.25 (negative FCF - burning cash) (Net Debt 377.0m / FCF TTM -7.36m)
Total Stockholder Equity = 822.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -3.78% (Net Income -51.9m / Total Assets 1.35b)
RoE = -6.31% (Net Income TTM -51.9m / Total Stockholder Equity 822.3m)
RoCE = -4.39% (EBIT -52.6m / Capital Employed (Equity 822.3m + L.T.Debt 374.2m))
RoIC = -3.42% (negative operating profit) (NOPAT -41.5m / Invested Capital 1.21b)
WACC = 6.13% (E(2.15b)/V(2.67b) * Re(7.52%) + D(522.5m)/V(2.67b) * Rd(0.49%) * (1-Tc(0.21)))
Discount Rate = 7.52% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.73 | Cagr: 1.65%
[DCF] Fair Price = unknown (Cash Flow -7.36m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.57 | # QB: 0
Revenue Correlation: 99.91 | Revenue CAGR: 10.75% | SUE: 1.97 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.05 | Chg30d=+0.00% | Revisions=-12% | Analysts=11
EPS current Year (2026-12-31): EPS=0.18 | Chg30d=+1.04% | Revisions=+22% | GrowthEPS=+53.8% | GrowthRev=+10.6%
EPS next Year (2027-12-31): EPS=0.34 | Chg30d=-0.27% | Revisions=-8% | GrowthEPS=+82.8% | GrowthRev=+10.0%
[Analyst] Revisions Ratio: +0% (up=10, down=10)